Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real‐world effectiveness study in Canada

OBJECTIVE: Liraglutide 3.0 mg is associated with clinically significant weight loss in clinical trials, but real‐world data are lacking. In this analysis, weight loss and persistence outcomes with liraglutide 3.0 mg were assessed across obesity classes, in a real‐world clinical setting. METHODS: Sec...

Descripción completa

Detalles Bibliográficos
Autores principales: Wharton, Sean, Haase, Christiane L., Kamran, Elham, Liu, Aiden, Mancini, Johanna, Neish, Drew, Pakseresht, Arash, Power, G Sarah, Christensen, Rebecca A. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Short Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448201/
https://www.ncbi.nlm.nih.gov/pubmed/32874678
http://dx.doi.org/10.1002/osp4.420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448201/
https://www.ncbi.nlm.nih.gov/pubmed/32874678
http://dx.doi.org/10.1002/osp4.420

Ejemplares similares